Who’s got the power? (06/08/2013)
This post was contributed by a representative of Montgomery Investment Management Pty Limited (AFSL No. 354564). The principal purpose of this post is to provide factual information and not provide financial product advice. Additionally, the information provided is not intended to provide any recommendation or opinion about any financial product. Any commentary and statements of opinion however may contain general advice only that is prepared without taking into account your personal objectives, financial circumstances or needs. Because of this, before acting on any of the information provided, you should always consider its appropriateness in light of your personal objectives, financial circumstances and needs and should consider seeking independent advice from a financial advisor if necessary before making any decisions. This post specifically excludes personal advice.
INVEST WITH MONTGOMERY
John Stanning
:
Excellent post Ben,I have followed Resmed over a number of years both on the ASX & XNYS.Interestingly on the xnys RMD was a traders dream from Feb2010 – June 2011,the stock channelled and on 7 occasions I traded it with tight stops for a return of between 7.5 – 12% on each occasion.This was not applicable to RMD on the asx, however as a buy and hold from feb 2010 to the current date RMD on the ASX has returned almost 250% as opposed to 90% on the XNYS !My original strategy was as a hedge against the AUD, now with our dollar under pressure, trading RMD on the xyns looks the better investment.
Roger Montgomery
:
Hi John,
A good example of how to really test any trading strategy: Does it beat buy and hold?
Peter Briggs
:
I recently came across TV program on current research trial for sleep apnoea. They quoted 50% intolerance of face masks (the subject was wearing a Resmed machine). This research was combining diet with medication and although early days results were promising. I suggest those with Resmed shares keep as close an eye on research as on ROE.